Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapies

Is there a role for rituximab in nephrotic syndrome?

Nature Reviews Nephrology volume 10, pages 245–247 (2014)Cite this article

Subjects

Anti-CD20 therapy is increasingly being used in the treatment of various patterns of nephrotic syndrome in adults and children. However, its use is still based largely on observational studies and expert opinion. Well-designed randomized controlled trials are urgently needed to define the role of this expensive therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ruggenenti, P. et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2013030251.

  2. Kattah, A. G., Fervenza, F. C. & Roccatello, D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun. Rev. 12, 854–859 (2013).

    Article  CAS  Google Scholar 

  3. Ravani, P. et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin. J. Am. Soc. Nephrol. 6, 1308–1315 (2011).

    Article  CAS  Google Scholar 

  4. Magnasco, A. et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 23, 1117–1124 (2012).

    Article  CAS  Google Scholar 

  5. Glassock, R. J. The pathogenesis of membranous nephropathy: evolution and revolution. Curr. Opin. Nephrol. Hypertens. 21, 235–242 (2012).

    Article  CAS  Google Scholar 

  6. Cara-Fuentes, G. et al. Rituximab in idiopathic nephrotic syndrome: does it make sense? Pediatr. Nephrol. http://dx.doi.org/10.1007/s00467-013-2534-4.

  7. Chan, A. C. Rituximab's new therapeutic target: the podocyte actin cytoskeleton. Sci. Transl. Med. 3, 85ps21 (2011).

    PubMed  Google Scholar 

  8. Gregersen, J. W. & Jayne, D. R. B-cell depletion in the treatment of lupus nephritis. Nat. Rev. Nephrol. 8, 505–514 (2012).

    Article  CAS  Google Scholar 

  9. Specks, U. et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 369, 417–427 (2013).

    Article  CAS  Google Scholar 

  10. Tony, H. P. et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res. Ther. 13, R75 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The John Walls Renal Unit, Leicester General Hospital, Gwendolen Road, Leicester, LE5 4PW, UK

    John Feehally

Authors
  1. John Feehally
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Feehally.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feehally, J. Is there a role for rituximab in nephrotic syndrome?. Nat Rev Nephrol 10, 245–247 (2014). https://doi.org/10.1038/nrneph.2014.37

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2014.37

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing